Beyond the Elevator Pitch | Inside Start-up Stories | Part 3
🦷 Do you already know the game changer against periodontitis?💡Periotrap has the answer.
As DCZHeadhunterAngels, we celebrate the drive and creativity of biotech entrepreneurs. That’s why we delve behind the elevator pitch of interesting start-ups and regularly feature them in our posts.
Today we take a look at PerioTrap Pharmaceuticals GmbH.
🎯 PerioTrap has cracked the code to tackle periodontitis. This clinical-stage biotech company is on a mission to eradicate the root cause of this chronic gum disease with a groundbreaking anti-infective drug.
Their innovative approach targets only the disease-causing pathogens, sparing the beneficial bacteria that support a healthy oral microbiome. No more broad-spectrum antibiotics disrupting the microbiome balance!
The secret weapon? An enzyme called glutaminyl cyclase (QC) type II, found exclusively in pathogenic bacteria within the oral biofilm, especially Porphyromonas gingivalis—the main culprit behind periodontitis.
With periodontitis impacting up to half the global population and being linked to serious conditions like diabetes and Alzheimer’s, PerioTrap offers a groundbreaking solution for better health.
📖 Read the full interview with the co-founder Pierre Tangermann and get the inside story of Periotrap.
